Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01546753 · ClinicalTrials.gov registry record · Phase 1
Walnut Oral Immunotherapy for Tree Nut Allergy
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01546753 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 22 participants.
The verdict
NCT01546753, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if walnut oral immunotherapy can be used in participants allergic to tree nuts to reduce tree nut allergy and induce changes in the participant's immune system.
Interventions
- DRUG Walnut Protein Powder
- DRUG Oat Powder (placebo)
- DRUG Open-label Walnut Protein Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-04-27 |
| Est. Completion | 2020-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01546753
The ClinicalTrials.gov registry entry for NCT01546753 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Walnut Protein Powder is the first listed.
NCT01546753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01546753 about?
NCT01546753 is a clinical study titled "Walnut Oral Immunotherapy for Tree Nut Allergy". The purpose of this study is to determine if walnut oral immunotherapy can be used in participants allergic to tree nuts to reduce tree nut allergy and induce changes in the participant's immune system.
What is the current status of trial NCT01546753?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2012-04-27. Estimated completion is 2020-07-02.
What interventions are being tested in trial NCT01546753?
The interventions under investigation include: Walnut Protein Powder (DRUG), Oat Powder (placebo) (DRUG), Open-label Walnut Protein Powder (DRUG).
Who is sponsoring clinical trial NCT01546753?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.